Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer

BackgroundA recent phase III clinical trial (NCT03981796) evaluated the efficacy and safety of dostarlimab combined with carboplatin-paclitaxel (DOS-CP) compared to placebo combined with carboplatin-paclitaxel (PLB-CP) as a first-line treatment for advanced endometrial cancer (EC). The NCT03981796 t...

Full description

Bibliographic Details
Main Authors: Maojin You, Xiaoling Zeng, Jinrong Zhang, Yufan Huang, Yalan Zhang, Zhongjie Cai, Yingying Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Immunology
Subjects:
dostarlimab
carboplatin-paclitaxel
cost-effectiveness
first-line treatment
endometrial cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267322/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267322/full

Similar Items